Who May Be Offered PGT Genetic Testing in IVF? Family History, Age and Prior Cycles Explained

The consent forms are already signed and the medication calendar is stuck to the fridge when the question arrives, almost as an afterthought: “Do you want to add genetic testing to your embryos?” One partner is nodding before the sentence finishes. The other is quietly doing arithmetic about how many embryos they can realistically expect, and what a test might take away.

That small, awkward pause is where most conversations about who needs PGT testing in IVF actually begin. Not in a genetics lecture, but at a kitchen table, with a decision that feels bigger than the leaflet suggests.

The honest answer is more textured than yes or no. Preimplantation genetic testing helps a specific set of people a great deal, offers uncertain value to another group, and can quietly work against a third. Sorting out which group you belong to is the whole point of this article.

Who needs PGT testing in IVF? The short version

Preimplantation genetic testing, usually shortened to PGT, is a laboratory analysis of a few cells taken from an embryo before it is transferred to the uterus. Its purpose is to check chromosomes or a specific gene so that the treating team can choose which embryo to transfer, and in what order.

Nobody is required to have it. In the United Kingdom, the NHS describes IVF as a sequence of ovarian stimulation, egg collection, fertilization and transfer; embryo testing sits outside that core pathway and is offered only in particular circumstances. The same is true in most US programs, where PGT is presented as an add-on that patients choose after counseling.

Three situations tend to move it from “available” to “worth a serious conversation”:

• A known inherited condition or a chromosomal rearrangement in one or both intended parents.
• Maternal age in the late 30s or older, when the proportion of embryos with the wrong number of chromosomes climbs.
• A history of repeated miscarriage or repeated transfers of good-looking embryos that did not implant.

Outside those groups, the evidence gets thinner. A large randomized trial found that adding chromosome screening did not increase overall ongoing pregnancy rates in good-prognosis patients when everyone in the study was counted, whether or not they ended up with an embryo to transfer. That finding sits at the heart of why thoughtful clinicians do not recommend PGT to every couple who walks in.

So the practical framing is this: PGT is a decision tool with a narrow set of strong indications and a wide gray zone. The rest of this piece walks through each, so the kitchen-table conversation has something firmer to stand on than a leaflet.

What PGT-A testing in IVF actually looks at

Most people who hear “genetic testing” in an IVF clinic are being offered PGT-A, where the A stands for aneuploidy. Aneuploidy simply means an embryo has a missing or extra chromosome, rather than the usual 23 pairs. Trisomy 21, the cause of Down syndrome, is one example; many other aneuploidies are incompatible with implantation or continued pregnancy.

PGT-A does not read every letter of the genome. Modern laboratories use next-generation sequencing, a method that counts how much DNA is present from each chromosome and flags gains or losses. Think of it as counting the volumes on a bookshelf, not proofreading each page. It will not detect a spelling mistake inside a single gene unless that gene has been specifically targeted, which is a different test.

Results usually come back in one of three broad categories:

• Euploid: the sampled cells show the expected chromosome count.
• Aneuploid: a whole chromosome, or a large segment, is missing or duplicated.
• Mosaic: the sample contains a mix of normal and abnormal cells, which makes prediction harder.

That last category is where honesty matters. The biopsy comes from the outer layer of the embryo, the part that will form the placenta, not the inner cells that become the baby. A mosaic result in that outer layer does not always reflect what is happening inside, and some embryos labeled mosaic have gone on to produce healthy pregnancies. Genetic counselors are careful to describe these as “reported” rather than “proven” abnormal.

What PGT-A offers, then, is a probability shift. It can lower the odds of transferring an embryo destined to fail for chromosomal reasons. It cannot promise that a euploid embryo will implant, because implantation also depends on the uterine lining, timing and factors medicine does not fully measure yet.

How the embryo biopsy actually happens, step by step

The IVF cycle itself runs as it would without testing. Ovaries are stimulated, eggs are collected under sedation, and sperm is introduced in the laboratory. The NHS notes that a full cycle typically spans roughly four to six weeks from the start of medication to transfer. Adding PGT changes the back half of that timeline, not the front.

Instead of transferring an embryo a few days after fertilization, the embryologist waits until day five or six, when a healthy embryo has become a blastocyst. A blastocyst is a hollow ball of roughly a hundred or more cells with a clear outer layer and an inner cell cluster. Only embryos that reach this stage can be biopsied, and not every fertilized egg will get there.

Using a fine glass pipette and, in most laboratories, a laser to open the shell, the embryologist gently removes a small cluster of cells, commonly five to ten, from the outer layer known as the trophectoderm. That layer is destined to become placenta, which is why the inner cells that form the fetus are left untouched.

Each embryo is then frozen using a rapid method called vitrification, essentially flash-freezing to a glass-like state that avoids ice crystals. The cells are sent to a genetics laboratory, and the embryos wait in storage until results arrive. Mayo Clinic’s patient guidance describes this freeze-and-wait pattern as the standard way PGT fits into IVF.

Transfer therefore happens in a later cycle, once the lining has been prepared again. People sometimes describe this as “losing a month,” which is fair, though many programs now favor frozen transfers regardless of testing, so the delay may be smaller than it first appears.

PGT-A, PGT-M and PGT-SR: which test fits which situation

The letters after PGT are not interchangeable, and the confusion between them is one reason people leave consultations unsure whether they were offered the right thing. Each test answers a different question, and each has a different profile of who it is for.

Test	What it checks	Typically discussed with	Key limitation
PGT-A	Number of chromosomes (aneuploidy)	Older maternal age, repeated miscarriage, repeated failed transfers, or by patient request	Cannot detect single-gene disorders; mosaic results are hard to interpret
PGT-M	A specific inherited gene variant (monogenic)	Couples who carry, or are affected by, a known single-gene condition such as cystic fibrosis, Huntington disease or sickle cell disease	Requires a known family variant and a custom lab set-up before the cycle
PGT-SR	Structural rearrangements such as translocations or inversions	A parent with a balanced chromosomal rearrangement, often found after recurrent loss	Distinguishes balanced from unbalanced embryos but not always carrier from non-carrier

PGT-M deserves particular emphasis because it is the version with the clearest rationale. When a family carries a condition with a one-in-four or one-in-two chance of affecting each pregnancy, testing embryos for that exact variant addresses a defined, measurable risk. MedlinePlus lists preimplantation testing among the recognized uses of genetic testing precisely for this scenario.

PGT-SR occupies similar ground. A person with a balanced translocation, where two chromosomes have swapped segments without losing material, is usually healthy but may produce a high share of unbalanced embryos. Testing lets the laboratory identify those.

PGT-A is the broadest and the most debated. It is not aimed at a known family risk; it screens for random errors that occur in everyone’s embryos to some degree. That difference explains why the evidence for PGT-A is more contested than for its siblings.

Family history: when a known inherited condition changes the conversation

Some families arrive at IVF not because of infertility at all, but because they already know what they are trying to avoid. A child lost to a metabolic disorder. A parent with Huntington disease watching symptoms appear in siblings. Two carriers of the same recessive variant discovered through routine screening before pregnancy.

For these people, the question of who needs PGT testing in IVF is close to settled. PGT-M can identify which embryos carry the family variant and which do not, giving the treating team the option of transferring only unaffected embryos. It requires groundwork: the specific variant must already be characterized, usually through testing of the affected relative or both parents, and the laboratory typically builds a tailored assay before egg collection begins. That preparation can add weeks to the front end of the process.

A few points are worth stating plainly, because they are often glossed over:

• PGT-M tests for the known variant only. It does not scan for every possible genetic condition.
• Results are highly accurate but not infallible; guidelines in the US and UK still advise confirmatory prenatal testing, such as chorionic villus sampling or amniocentesis, if a pregnancy follows.
• Some families choose not to test, preferring natural conception with prenatal diagnosis, or accepting the risk outright. That is a legitimate path, not a failure of planning.

Structural rearrangements form the other family-history route. A balanced translocation is often discovered only after two or more miscarriages prompt parental karyotyping, a blood test that lays out all chromosomes for inspection. Once found, PGT-SR becomes a rational option, because a meaningful fraction of that person’s embryos will carry an unbalanced version that rarely survives.

The pattern in this group is what makes the decision cleaner: the risk is known, specific and measurable, and the test is designed for exactly that risk.

Age and prior cycles: why the discussion changes after 35

Eggs are formed before birth and age with the body that carries them. As the years pass, the machinery that separates chromosomes during the final stages of egg maturation becomes less reliable, so a larger share of embryos end up with the wrong count. The NHS and Mayo Clinic both note that IVF outcomes decline with maternal age, and chromosomal error is a major reason.

This is why the age line in most counseling conversations falls somewhere in the mid to late 30s. Below it, a majority of blastocysts from a typical cycle are expected to be euploid, and picking one by appearance alone is a reasonable strategy. Above it, especially past 40, the odds flip, and a good-looking embryo is more likely than not to carry an error the microscope cannot see.

Prior cycles tell a related story. Two or more miscarriages, or several transfers of well-graded embryos that never implanted, raise the suspicion that chromosome errors are the recurring culprit. Testing does not fix that biology; it can, however, help avoid transferring embryos that were unlikely to succeed, which may shorten the path to a viable pregnancy or clarify that the embryo supply is the limiting factor.

Two cautions keep this from becoming a sales pitch:

• Older patients often produce fewer eggs, so fewer embryos reach the blastocyst stage to be biopsied at all. Some cycles end with nothing to test.
• Screening out abnormal embryos does not create normal ones. If every embryo in a cycle is aneuploid, PGT reveals that reality sooner but does not change it.

For many people in this group, the real benefit is information: knowing whether to try another retrieval, consider donor eggs, or pause. Framed that way, PGT-A is less a treatment than a map.

Who is usually asked to wait, or told testing adds little

Not every patient who asks for PGT is encouraged to have it, and that is not gatekeeping. Some situations make testing unhelpful, and a few make it counterproductive.

The clearest example is the younger patient with no family history and no prior losses. When most embryos are already expected to be euploid, screening removes relatively few and exposes every embryo to biopsy and freezing for a modest gain. The randomized trial discussed later found no overall improvement in this good-prognosis group once every participant was counted.

People who produce very few eggs sit in a second category. If a cycle yields one or two blastocysts, there may be little to choose between, and a report of “mosaic” or “no result” on the only embryo can create agonizing uncertainty rather than clarity. Some teams suggest transferring untested in this scenario, or banking embryos over several cycles before testing any of them.

A third group is asked to wait for a different reason: the preparatory work is not done. PGT-M cannot start until the family variant is identified and the laboratory has built its assay. Rushing into stimulation before that step risks a batch of frozen embryos with no way to test them for the condition that mattered.

Finally, some patients are gently steered away because their expectations do not match what the test delivers. Someone hoping PGT will guarantee a healthy baby, screen for autism, or rule out every birth defect is likely to be disappointed, and a good clinician will say so before any consent is signed.

Waiting is not refusal. In most of these cases it means gathering the information that makes the eventual decision, whichever way it goes, a sound one.

Is PGT testing worth it? What the trials actually show

Ask whether PGT-A is worth it and you will hear passionate answers on both sides. The evidence is more measured than either camp tends to admit.

The best-known randomized trial, published in Fertility and Sterility and indexed on PubMed, enrolled women aged 25 to 40 with a reasonable number of blastocysts and randomly assigned them to transfer based on PGT-A results or on embryo appearance alone. In the primary analysis, which counted every participant including those who ended up with no euploid embryo to transfer, ongoing pregnancy rates did not differ significantly between the two groups.

Two details give that finding texture. First, when the analysis looked only at people who actually had a transfer, and specifically at the 35 to 40 age band, the tested group did better per transfer. Second, that per-transfer advantage disappears in the overall picture partly because testing sometimes leaves patients with nothing to transfer, and those cycles count as failures.

Put together, the trial suggests:

• PGT-A can improve the odds that any single transfer succeeds, most visibly in the late 30s.
• It does not appear to raise the chance that a given egg retrieval eventually produces a pregnancy, because it removes embryos rather than repairing them.
• Benefits may include fewer miscarriages and fewer transfers before success, though trials have not consistently shown this.

What the evidence does not support is the idea that PGT-A is a universal upgrade. Nor does it support the opposite claim that the test is useless; for the right patient, reaching the same destination with fewer transfers and fewer losses is a meaningful outcome. Whether that trade is worth the biopsy, the delay and the risk of a confusing mosaic result is a judgment your treating team should make with you, not for you.

Can you do IVF without genetic testing? Yes, and most people do

Standard IVF has never required embryo testing. The NHS describes the ordinary pathway as fertilization in the laboratory followed by transfer of the best-looking embryo a few days later, with any remaining good-quality embryos frozen. Millions of children have been born through exactly that route.

Choosing IVF without genetic testing means the embryologist selects embryos using morphology, the visual grading of cell number, symmetry and the appearance of the blastocyst. It is imperfect, because a beautiful embryo can carry a chromosomal error, but it is also free of biopsy risk and adds no delay.

People who skip PGT still have access to information later. Prenatal screening in the first trimester, including the blood test that analyzes fragments of placental DNA in the mother’s circulation, often called cell-free DNA or non-invasive prenatal testing, can flag the most common aneuploidies. Diagnostic tests such as chorionic villus sampling, which samples placental tissue, and amniocentesis, which samples fluid around the fetus, remain available to confirm any concern. MedlinePlus groups all of these under the recognized uses of genetic testing.

There are trade-offs on this side too. Without PGT, a proportion of transfers will fail or miscarry for chromosomal reasons that testing might have anticipated. For someone who has already endured several losses, that possibility carries real weight. For someone in their early 30s on a first cycle with a healthy embryo count, it may be a reasonable risk to accept.

The point is that untested IVF is not the lesser option. It is the baseline against which any add-on must prove itself, and for a large share of patients the baseline holds up well.

Does PGT rule out Down syndrome? Mostly, but not completely

This is one of the most searched questions about PGT testing and Down syndrome, and it deserves a precise answer. Down syndrome results from an extra copy of chromosome 21, a condition MedlinePlus describes as the most common chromosomal cause of intellectual disability. Because PGT-A counts chromosomes, an embryo with three copies of chromosome 21 would ordinarily be reported as aneuploid and would not be prioritized for transfer.

So the short version is that PGT-A substantially lowers the chance of transferring an embryo with trisomy 21. Where it falls short is in the word “rule out.”

• The biopsy samples only a handful of outer cells. Rarely, those cells are normal while the inner cells carry an extra chromosome, or the reverse, a situation known as mosaicism.
• Laboratory error, though uncommon, is possible in any test.
• A euploid report speaks to whole-chromosome number. It does not address small deletions below the test’s resolution or single-gene variants unless PGT-M was also performed.

For these reasons, professional guidance in both the US and UK continues to recommend that pregnancies conceived after PGT be offered the same prenatal screening and, where appropriate, diagnostic testing as any other pregnancy. Clinicians describe PGT as reducing risk, never as eliminating it.

One more nuance matters for families choosing whether to test at all. Down syndrome is one of the few aneuploidies compatible with a healthy live birth, and many people live full lives with it. Some prospective parents want to avoid it; others do not see it as a reason to test. PGT offers information, and what a family does with that information is theirs to decide, ideally with a genetic counselor who can talk through both the science and the values involved.

What the following weeks usually look like after a PGT cycle

The rhythm of a PGT cycle is different from standard IVF mainly in its pauses. Knowing where they fall makes the waiting easier to plan around.

The stimulation and retrieval phase runs as usual. Once eggs are fertilized, the laboratory watches development for five to six days, and only embryos that reach the blastocyst stage are biopsied and frozen. Families are often told how many embryos were biopsied within a day or so of that step; this is the first number that shapes expectations.

The genetics laboratory then needs time to process the samples. Turnaround varies between laboratories and by test type; PGT-M, with its custom assay, typically takes longer than PGT-A. Your clinic will give a specific estimate, and it is worth asking for it in writing so the wait has an end date.

When results arrive, most programs schedule a consultation rather than sending a bare report. That conversation covers how many embryos are euploid, aneuploid, mosaic or without result, and how the team proposes to rank them. This is also the moment to raise the mosaic question, because some centers will consider transferring certain mosaic embryos after counseling while others will not.

Transfer then happens in a separate frozen embryo transfer cycle. The uterine lining is prepared, usually with hormonal medication, and the chosen embryo is thawed and placed a few days after the lining is judged ready. A pregnancy test follows roughly two weeks later, consistent with the timeline the NHS describes for embryo transfer and testing.

Emotionally, people describe the results call as the hardest wait. Practically, the entire sequence from egg collection to transfer often spans two menstrual cycles rather than one. Planning work and travel around that longer horizon spares some unnecessary stress.

What people often get wrong about who needs PGT testing in IVF

Misunderstandings about PGT are not a sign of carelessness. The terminology is dense, marketing language is everywhere, and well-meaning friends pass along half-remembered facts. A few corrections clear most of the fog.

“Everyone doing IVF should test.” The randomized evidence does not support blanket use. Benefit is most plausible in the late 30s and beyond, and in people with repeated losses; in younger good-prognosis patients, overall outcomes were not improved.

“A euploid embryo is a guaranteed pregnancy.” A normal chromosome count improves the odds per transfer, but euploid embryos still fail to implant for reasons unrelated to chromosomes. No laboratory can promise a result, and any clinic that implies otherwise is overselling.

“PGT screens for everything.” PGT-A counts chromosomes. PGT-M looks for one specified variant. Neither scans the whole genome for every possible condition, and neither predicts traits like intelligence or personality.

“Testing makes more good embryos.” It cannot. Testing sorts what already exists. If a cycle produces only abnormal embryos, the test reveals that; it does not alter it.

“The biopsy harms the baby.” The cells are taken from the layer that becomes placenta, not from the fetal cells. Follow-up studies of children born after PGT have been broadly reassuring, though the possibility of subtle embryo damage from biopsy and freezing is one reason the procedure is not offered casually.

“Mosaic means abnormal.” Mosaic results are uncertain results. Healthy children have been born from embryos reported as mosaic, and many programs now discuss transferring them after counseling when no euploid embryo is available.

“Once you test, you never need prenatal screening.” Guidance still recommends offering standard prenatal screening and diagnostic testing after PGT, because no embryo test is perfect.

Questions to ask your care team before deciding

The consultation where PGT is raised is often brief, and it tends to happen while attention is on medication schedules and monitoring appointments. Bringing a prepared list turns a rushed yes-or-no into an informed choice. The questions below are the ones genetic counselors say patients most often wish they had asked.

• Given my age, history and previous cycles, do you consider PGT strongly indicated, optional, or unlikely to help me?
• Which type of PGT are you proposing, and what specifically will it and will it not detect?
• How many blastocysts do you expect from my cycle, and what happens if only one or two are available to biopsy?
• What is your laboratory’s typical turnaround for results, and how will they be communicated to me?
• How does your program handle mosaic results and embryos that return no result?
• What is your policy on transferring embryos reported as mosaic if no euploid embryo is available?
• Would you recommend banking embryos over more than one retrieval before testing?
• If I decline testing, how will you select which embryo to transfer, and would you still recommend a frozen transfer?
• What prenatal screening or diagnostic testing would you advise during a pregnancy conceived after PGT?
• Can I speak with a genetic counselor before I decide?

Two further points are worth raising even though they are not strictly medical. Ask how long embryos can remain in storage under your program’s policies and local regulation, and ask what happens to embryos reported as aneuploid, since options range from discarding to donation for research and vary by jurisdiction and by personal belief.

None of these questions has a single right answer. Their value is in surfacing your team’s reasoning so the final decision, which remains yours and theirs together, rests on your circumstances rather than on a default.

When to call your doctor

PGT itself happens in a laboratory dish, so it carries no direct physical risk to you. The IVF cycle around it does, and the frozen transfer that follows brings its own set of things to watch. Knowing the red flags means you can act quickly rather than second-guessing yourself.

During and shortly after ovarian stimulation and egg collection, contact your clinic the same day if you notice:

• Severe or rapidly worsening abdominal pain or bloating, especially with nausea or vomiting.
• Sudden weight gain over a day or two, or a noticeably swollen abdomen.
• Passing much less urine than usual, or feeling dizzy and faint.
• Shortness of breath, chest pain, or a swollen, painful calf.

These can signal ovarian hyperstimulation syndrome, a reaction to fertility medication that the NHS and Mayo Clinic both flag as an uncommon but potentially serious complication, or a blood clot. Both warrant urgent assessment.

After egg collection, seek same-day advice for a fever, heavy vaginal bleeding, or pelvic pain that is getting worse rather than better. Mild cramping and light spotting are expected; escalating pain is not.

Following a frozen embryo transfer, call promptly for heavy bleeding, severe one-sided pelvic pain, shoulder-tip pain, or fainting, particularly once a pregnancy test is positive. These can indicate an ectopic pregnancy, where the embryo implants outside the uterus, which needs immediate care.

Emotional distress counts too. The wait for genetic results and the possibility of an unexpected report can be overwhelming, and most programs have counselors available. Reaching out is part of good care, not a sign of not coping.

Every decision about testing, transfer, or further cycles sits with your treating team, who know your history and your results. When in doubt about a symptom, the right call is always to ask rather than wait.

Frequently asked questions

Can you do IVF without PGT testing?

Yes. Standard IVF selects embryos by their appearance under the microscope and does not involve any genetic testing. The NHS describes this as the usual pathway, and the large majority of IVF pregnancies worldwide have been conceived this way. Prenatal screening and diagnostic tests remain available during the pregnancy if you want chromosomal information later.

Is a PGT test mandatory for IVF?

No. PGT is offered as an optional addition after counseling, and no fertility program requires it as a condition of treatment. Some clinicians recommend it more strongly for particular groups, such as carriers of an inherited condition or people with repeated miscarriages, but the decision to accept or decline always rests with the patient and treating team together.

Is PGT testing worth it for IVF?

It depends on who you are. For carriers of a known genetic condition, PGT-M addresses a specific risk and is widely regarded as worthwhile. For PGT-A, a randomized trial found no overall improvement in good-prognosis patients, with a possible per-transfer benefit in the late 30s. For younger patients without risk factors, many teams consider it optional rather than valuable.

Does PGT rule out Down syndrome?

Not completely. PGT-A counts chromosomes and would usually identify an embryo with an extra chromosome 21, so it greatly reduces the chance of transferring one. Because the biopsy samples only a few outer cells, and because mosaicism and laboratory error are possible, guidance still recommends offering prenatal screening and diagnostic testing after a PGT pregnancy.

What is PGT-A testing in IVF and how is it different from PGT-M?

PGT-A screens embryos for the wrong number of chromosomes, a random error that becomes more common with maternal age. PGT-M looks for one specific inherited gene variant that runs in a family, such as the variant causing cystic fibrosis. PGT-A is a general screen; PGT-M is a targeted test that requires the family variant to be known in advance.

At what age is PGT usually discussed?

Most counseling conversations place the line somewhere in the mid to late 30s, because the proportion of embryos with chromosomal errors rises with maternal age and the trial evidence for a per-transfer benefit is strongest between 35 and 40. Below that age, in the absence of other risk factors, many teams describe PGT-A as optional.

Does the embryo biopsy harm the embryo?

The cells are removed from the outer trophectoderm layer, which becomes placenta, not from the inner cells that form the fetus. Follow-up studies of children born after PGT have been broadly reassuring. Even so, biopsy and freezing are interventions, and the small possibility of embryo damage is one reason clinicians do not recommend testing for everyone.

What does a mosaic embryo result mean?

A mosaic result means the sampled cells contained a mix of normal and abnormal chromosome counts. It is an uncertain finding rather than a diagnosis, because the outer layer may not match the inner cells. Healthy children have been born from embryos reported as mosaic, and some programs will discuss transferring them after counseling when no euploid embryo is available.

How long does IVF with genetic testing take compared with standard IVF?

The stimulation and retrieval phase is the same; the NHS estimates a full standard cycle at roughly four to six weeks. With PGT, embryos are biopsied at day five or six, frozen, and transferred in a later cycle once results return. In practice the sequence from egg collection to transfer often spans two menstrual cycles rather than one.

Do I still need prenatal screening after IVF with genetic testing?

Yes, it is still offered. PGT reduces the chance of a chromosomal condition but cannot eliminate it, because only a few cells are tested and mosaicism can occur. Guidance in the US and UK recommends that pregnancies conceived after PGT be offered the same first-trimester screening and, where appropriate, diagnostic testing as any other pregnancy.

References

• NHS: IVF, what happens
• NHS: IVF overview
• MedlinePlus Genetics: What are the uses of genetic testing?
• MedlinePlus Genetics: Down syndrome

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.